December 16, 2021–Today, DISPENDIX, a BICO company, announced the launch of the I.DOT DW, the newest system in the I.DOT series of products. The I.DOT is the only instrument in the world to incorporate a built-in drop detection system and has the capability to detect when users run out of source liquid, while at the same time verifies dispensing volume.
Building on the market leading I.DOT drop detection system, the patented DropDetection feature detects and counts every droplet released during a single dispending run, at an optimal speed. The system also eliminates carryover and cross-contamination by enabling droplets to be dispensed into the target plate below the source plate. I.DOT DW automates life science workflows and executes them more efficiently than seen before.
“As pioneers in the liquid handling space, we are pleased to continue to share new solutions on our journey to create the future of health,” said Petros Apostolopoulos, CEO of DISPENDIX. “We are excited to introduce this product to researchers to optimize workflows, and bring a new level of automation, precision and speed to all labs in the life science industry.”
The I.DOT DW carries out precise and accurate noncontact liquid handling tasks via eight individually controlled positive pressure channels that generate droplets from 8 to 50 nanoliters from a small nozzle at the bottom of each well. Each channel can generate up to 100 droplets per second giving control and speed to the users all while eliminating cross contamination.
This launch is the latest in DISPENDIX’s mission to deliver simple and elegant solutions for nanoliter dispensing. The I.DOT DW is now available; those interested can visit https://dispendix.com/i-dot-dw/ or contact firstname.lastname@example.org
DISPENDIX GmbH, the premier provider of noncontact liquid handling solutions in the nano to microliter range, started out in 2016 as a spin-off from the Fraunhofer Institute for Manufacturing Engineering and Automation (IPA) in Stuttgart, Germany. In 2018, DISPENDIX joined the world’s leading bio convergence company BICO, which now encompasses 900+ colleagues and 11 companies, offering a portfolio of technologies, products and services to create the future of health. Part of that portfolio is DISPENDIX’s patented and widely recognized technology, the I.DOT, which brings intuitive automation, precision, and speed to every lab, allowing scientists to optimize liquid handling workflows and accelerate their research in a range of applications. DISPENDIX’S Liquid handling technology enables new discoveries in areas such as drug development, diagnostics and synthetic biology. We believe that technological advances and science are made for each other. Good technology simplifies science. www.dispendix.com
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better. The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com